Dissection of the Effects of JAK and BTK Inhibitors on the Functionality of Healthy and Malignant Lymphocytes
Open accessThe DOI matches its Crossref record; 48 of the 50 references it cites were found in a registry or an index.
Abstract
Despite the emergence of small molecule inhibitors, current treatment strategies for chronic lymphocytic leukemia (CLL) are not curative, and the search for new therapeutic modalities continues. Prosurvival signaling derived from the microenvironment is often mediated via JAK signaling. However, whether JAK inhibitors are useful in CLL therapy has not been studied extensively. JAK inhibitors are valuable therapeutic agents in myelofibrosis and show promising results in graft-versus-host-disease. However, JAK inhibition is associated with an increased infection risk, presumably because of the effect on other immune cells, a feature shared with other kinase inhibitors used for CLL treatment, such as the BTK inhibitor ibrutinib and the PI3Kδ inhibitor idelalisib. We compared functional effects of the JAK1/2 inhibitors momelotinib and ruxolitinib, the BTK inhibitors ibrutinib and tirabrutinib, and PI3Kδ inhibitor idelalisib on malignant CLL cells but also on healthy human T, B, and NK lymphocytes. We found several interesting differences among the inhibitors, apart from expected and well-known effects. Momelotinib but not ruxolitinib blocked cytokine-induced proliferation of CLL cells. Momelotinib also reduced BCR signaling, in contrast to ruxolitinib, indicating that these JAK inhibitors in fact have a distinct target spectrum. In contrast to tirabrutinib, ibrutinib had inhibitory effects on T cell activation, probably because of ITK inhibition. Remarkably, both BTK inhibitors stimulated IFN-γ production in a mixed lymphocyte reaction. Collectively, our results demonstrate that kinase inhibitors directed at identical targets may have differential effects on lymphocyte function. Their unique profile could be strategically employed to balance desired versus unwanted lymphocyte inhibition.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ibrutinib has also been suggested to limit CTL and NK-cell proliferation and effector functions in response to activating stimuli”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Hofland et al., 2019
Citations
Cites
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824 · cited 1×
“Although NK cells do not require stimulation via cytokines, cytokines can increase the magnitude of NK cell responses (37).”
BackgroundA double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Roberts, A. W., Davids, M. S., Pagel, J. M., Kahl, B. S., Puvvada, S. D., Gerecitano, J. F., Kipps, T. J., Anderson, M. A., Brown, J. R., Gressick, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1513257 · Cited by 1,900 · cited 1×
“inhibitor venetoclax and Bruton tyrosine kinase (BTK) inhibitor ibrutinib have shown substantial clinical efficacy in most CLL patients (2, 3).”
BackgroundJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639 · cited 1×
“inhibitor venetoclax and Bruton tyrosine kinase (BTK) inhibitor ibrutinib have shown substantial clinical efficacy in most CLL patients (2, 3).”
BackgroundResistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400029 · Cited by 1,275
Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood · doi:10.1182/blood-2013-06-507947 · Cited by 810 · cited 8×
“reports on off-target ITK inhibition (26, 27)].”
BackgroundInfluentialPathophysiology of Chronic Graft-versus-Host Disease and Therapeutic Targets
Zeiser, R., & Blazar, B. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1703472 · Cited by 748 · cited 1×
“pathology (45), and ruxolitinib has clinical efficacy in refractory GvHD patients (46).”
BackgroundZeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., et al. (2015) · Leukemia · doi:10.1038/leu.2015.212 · Cited by 539 · cited 1×
“pathology (45), and ruxolitinib has clinical efficacy in refractory GvHD patients (46).”
BackgroundKipps, T. J., Stevenson, F. K., Wu, C. J., Croce, C. M., Packham, G., Wierda, W. G., O'Brien, S., Gribben, J., & Rai, K. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.96 · Cited by 517 · cited 1×
“may pose a significant problem for already frail CLL patients, where infections are a leading cause of death (1).”
Background
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
The Impact of Pre-existing Comorbidities and Therapeutic Interventions on COVID-19
Callender, L. A., Curran, M., Bates, S. M., Mairesse, M., Weigandt, J., & Betts, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01991 · Cited by 188
“Mild/moderate COVID-19 is characterized by local inflammation, the recruitment of monocytes, DCs, NK cells, T and B cells, followed by resolution of the infection and inflammation.”
BackgroundInfluentialT-cells in chronic lymphocytic leukemia: Guardians or drivers of disease?
Roessner, P. M., & Seiffert, M. (2020) · Leukemia · doi:10.1038/s41375-020-0873-2 · Cited by 144
Zhu, S., Gokhale, S., Jung, J., Spirollari, E., Tsai, J., Arceo, J., Wu, B. W., Victor, E., & Xie, P. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.727531 · Cited by 59
“Ibrutinib potently suppresses anti-CD20-induced calcium mobilization, IFNγ production, degranulation and cytotoxicity of NK cells, which all appear to be ITK-dependent, as these NK cell functions are not affected by more selective BTK inhibitors, including acalabrutinib, zanubrutinib or CGI-1746 (Kohrt et al., 2014; D…”
BackgroundBruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect
Wang, H., Guo, H., Yang, J., Liu, Y., Liu, X., Zhang, Q., & Zhou, K. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00315-9 · Cited by 36
“Tirabrutinib possibly has no effect on T-cell function [69].”
Background
Metadata
- Authors
- Hofland, T., de Weerdt, I., ter Burg, H., de Boer, R., Tannheimer, S., Tonino, S. H., Kater, A. P., & Eldering, E.
- Affiliations
- Amsterdam University Medical Centers (NL)
- Department of Experimental Immunology, Amsterdam Infection and Immunity Institute, Amsterdam University Medical Centers, University of Amsterdam , 1105 AZ Amsterdam ,
- Gilead Sciences (United States) (US)
- Corresponding author
- Hofland, Tom
- Eldering, Eric
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-10
- Volume
- 203
- Issue
- 8
- Pages
- 2100-2109
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2973205945
- Cited by
- 21
- References
- 50
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 1
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Life Sciences › Immunology and Microbiology › Immunology › Immunodeficiency and Autoimmune Disorders
- Keywords
- chronic lymphocytic leukemia, JAK inhibitors, BTK inhibitors, momelotinib, ruxolitinib, ibrutinib, tirabrutinib, idelalisib, B cell receptor signaling, T cell activation, IFN-gamma production, lymphocyte proliferation, infection risk
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Animals, Antineoplastic Agents, Benzamides, Cell Survival, Humans, Imidazoles, Lymphocytes, Nitriles, Piperidines, Purines, Pyrazoles, Pyrimidines, Leukemia, Lymphocytic, Chronic, B-Cell, NIH 3T3 Cells, Protein Kinase Inhibitors, Cell Proliferation, Mice, Quinazolinones, Janus Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.